Selenium‐Containing 1,4‐Naphthoquinone Derivatives Trigger Reactive Oxygen Species and Apoptosis in Triple‐Negative Breast Cancer Cells
Drug Development Research · 2026
DOI: 10.1002/ddr.70332 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Eduardo Angulo-Elizari und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Ciencias Farmacéuticas, Universidad de Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Naphthoquinones, Reactive Oxygen Species, Antineoplastic Agents, Triple Negative Breast Neoplasms. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: PIUNA, Department of Pharmacology, Penn State College of Medicine (PSCOM), Penn State Cancer Institute (PSCI).
Abstract (Originalsprache)
Cancer ranks as a leading cause of death worldwide, demanding new affordable therapies. Nature offers a diverse array of bioactive scaffolds, including 1,4‐naphthoquinone, which serves as a precursor for numerous natural and synthetic compounds with potent antitumor properties. Selenium, an essential trace element, has shown significant potential in medicinal chemistry when incorporated into organic molecules. In this study, we synthesized 24 novel selenium‐containing derivatives based on menadione (series A) and 1,4‐naphthoquinone (series B), incorporating selenium as selenoester and selenocyanate functionalities. Initial cytotoxic screening at 25 and 10 µM against four cancer cell lines (MDA‐MB‐231, PC‐3, HTB‐54 and HCT‐116) identified five active compounds, with B2 and B8 exhibiting the highest potency and selectivity against breast cancer cells. Further biological evaluation via the NCI Developmental Therapeutics Program confirmed their apoptosis induction and antiproliferative activity through reactive oxygen species (ROS) production. Molecular dynamics simulations additionally suggest that B2 and B8 may act as topoisomerase II alpha inhibitors. These results position compounds B2 and B8 as promising candidates for breast cancer therapy, paving the way for further investigation into their potential as chemotherapeutic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Ciencias Farmacéuticas, Universidad de Navarra, Pamplona, Spain.
- Department of Pharmacology, Penn State Cancer Institute, CH72, Penn State College of Medicine, Hershey, Pennsylvania, USA.
- Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
- Departamento de Ciencias de la Salud, Universidad Pública de Navarra, Pamplona, Spain.
ORCID-Profile: Carmen Sanmartín
Förderung
- PIUNA
- Department of Pharmacology, Penn State College of Medicine (PSCOM)
- Penn State Cancer Institute (PSCI)
Zitieren
APA
Angulo-Elizari, E., Raza, A., Johnson, H., Martínez-Sáez, N., Encío, I., Sharma, A. K., Sanmartín, C., & Plano, D. (2026). Selenium‐Containing 1,4‐Naphthoquinone Derivatives Trigger Reactive Oxygen Species and Apoptosis in Triple‐Negative Breast Cancer Cells. Drug Development Research. https://doi.org/10.1002/ddr.70332
Vancouver
Angulo-Elizari E, Raza A, Johnson H, Martínez-Sáez N, Encío I, Sharma AK, et al. Selenium‐Containing 1,4‐Naphthoquinone Derivatives Trigger Reactive Oxygen Species and Apoptosis in Triple‐Negative Breast Cancer Cells. Drug Development Research. 2026. doi:10.1002/ddr.70332
BibTeX
@article{AnguloElizari2026,
author = {Angulo-Elizari, Eduardo and Raza, Asif and Johnson, Hannah and Martínez-Sáez, Nuria and Encío, Ignacio and Sharma, Arun K and Sanmartín, Carmen and Plano, Daniel},
title = {Selenium‐Containing 1,4‐Naphthoquinone Derivatives Trigger Reactive Oxygen Species and Apoptosis in Triple‐Negative Breast Cancer Cells},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70332}
}
EUVIMED